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Antioxidant activityAbstract The oxadiazole pharmacophore is considered a viable lead structure for the synthesis of
more efﬁcacious and broad spectrum antimicrobial agents. The signiﬁcance of this study was to pre-
pare various oxadiazole derivatives by introducing the 1,3,4 oxadiazole core into several molecules
to explore the possibilities of some altered biological activities. Therefore, the study presents the
synthesis, antimicrobial and antioxidant evaluation of a series of 1,3,4 substituted oxadiazole deriv-
atives. Antimicrobial evaluation revealed that eighteen compounds were able to display variable
growth inhibitory effects on the tested Gram-positive bacteria Bacillus subtilis and Staphylococcus
aureus, Gram-negative bacteria Pseudomonas aeruginosa and Escherichia coli and fungal strains
Candida albicans and Aspergillus niger. Among the synthesized derivative analogues 6f, 6l and 6r
were found to be the most effective antibacterial agents. While the compounds 6c, 6l and 6q were
found to be the most promising antifungal agents. On the other hand, all the synthesized com-
pounds 6a–6r were subjected to antioxidant activity but only analogues 6l and 6q were found to
exhibit potent antioxidant activity. Further compound 6l containing p-nitro phenyl moiety along
with oxadiazole pharmacophore proved to be the most active antimicrobial and antioxidant agent.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
One of the main objectives of organic and medicinal chemists is
to design and synthesize molecules having therapeutic values
(Verma and Saraf, 2008). The dramatically rising prevalence
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ades has become a serious health care problem. In, the past
25 years, the incidence of microbial infection has increased in
alarming levels all over the world as a result of antimicrobial
resistance. A growing number of immuno-compromised pa-
tients (immune response attenuated by administration of immu-
nosuppressive drugs) as a result of cancer chemotherapy, organ
transplantation andHIV infection are themajor factors contrib-
uting to this increase (Koca et al., 2005; Bonde and Gaikwad,
2004; Yu and Huiyuan, 2002; Ram, 1988). Hence there will al-
ways be a vital need to discover new chemotherapeutic agents
to avert the emergence of resistance and ideally shorten the dura-
tion of therapy (Dolman et al., 2006; Murphy et al., 2007).
A wide variety of heterocyclic systems have been explored for
developing pharmaceutically important molecules. Nitrogen
containing heterocyclic molecules constitutes the largest portion
of chemical entities, which are part ofmany natural products, ﬁne
chemicals, and biologically active pharmaceuticals (Khalil et al.,
1980). Among them the derivatives of oxadiazoles played a very
important role in themedicinal chemistry. Oxadiazoles have been
described as bio-isosteres for amides and esters (Jonathan and
Robert, 1998). Due to increased hydrolytic (Clapp, 1976) and
metabolic stabilities of the oxadiazole ring, improved pharmaco-
kinetic and in vivo performance is often observed, which make
these heterocycles an important structural motif for the pharma-
ceutical industry. 1,3,4-oxadiazoles are an important class of het-
erocyclic compounds with a variety of biological activities.
Substituted 1,3,4-oxadiazoles have shown antibacterial and anti-
fungal (Gaonkar et al., 2006), antioxidant (Padmavathi et al.,
2011), anticancer (Bhatt et al., 1994), antimycobacterial (Tanga-
llapally et al., 2007), antimalarial (Kagthara et al., 1999), antihy-
poglycemic (Hussian et al., 1986), anti-inﬂammatory (Palaska
et al., 2002), anticonvulsant (Zarghi et al., 2005) andmuscle relax-
ant (Yale and Losee, 1966), genotoxic (Maslat et al., 2002), and
insecticidal activities (Shi et al., 2001). They are also used exten-
sively in the symptomatic treatment of rheumatic fever, arthritis
(rheumatoid, osteo and jaundice arthritis), and management of
primary dysmennorrhoea (Cao et al., 2003). Oxadiazole pharma-
cophore has the key property that inﬂuences the ability of a drug
to reach the target by transmembrane diffusion and show potent
antimicrobial activity (Testa et al., 2000).
The wide range of therapeutic values of 1,3,4-substituted
oxadiazole ring systems promoted us to synthesize the title com-
pounds and screen them for their antimicrobial and antioxidant
activities. Therefore, it was envisaged that chemical entities with
Schiff base and oxadiazole moieties would result in compounds
of interesting biological activities. In view of these ﬁndings, we
have attempted to incorporate all two biologically active com-
ponents together to give the title compounds for evaluating their
antimicrobial and antioxidant activities inspired by the above
facts and in continuation of our ongoing research programme
in the ﬁeld of synthesis and antimicrobial activity of medicinally
important compounds (Deep et al., 2010, 2012;Madhukar et al.,
2009). In this communication we are reporting the synthesis of
1,3,4-substituted oxadiazole derivatives and evaluated them
for antimicrobial and antioxidant activities.2. Materials and methods
Melting points of the synthesized compounds were determined
in open-glass capillaries on a Stuart SMP10 melting pointapparatus and were recorded as uncorrected. The purity of
the compounds was checked by thin layer chromatography
(TLC). Silica gel plates kieselgel 0.25 mm, 60 GF254, precoated
sheets obtained from Merck, Darmstadt (Germany) were used
for TLC and the spots were visualized by iodine vapours/ultra-
violet light as visualizing agent. The IR spectra (t, cm1) were
obtained with a Perkin-Elmer 1600 FTIR spectrometer in KBr
pellets. 1H-NMR spectra (d, ppm) were recorded in DMSO-d6
solutions on a Varian–Mercury 300 MHz spectrometer using
tetramethylsilane as the internal reference. 13C-NMR spectra
were recorded in dimethylsulphoxide (DMSO)-d6 solutions
on a Bruker Avance II 400 spectrometer at 400 MHz using tet-
ramethylsilane as the internal reference. Elemental analyses
were performed on an ECS 4010 Elemental Combustion Sys-
tem. The necessary chemicals were purchased from Loba Che-
mie, Fluka and Sigma Aldrich.
3. Chemistry
The syntheses of targeted compounds were carried out as out-
lined in synthetic scheme. Compounds (6a–6r) were readily pre-
pared in good yields and purity. Initially biphenyl-4-carboxylic
acid (1) and excess of methanol with a catalytic amount of sul-
phuric acid were reﬂuxed for 5 h to form biphenyl-4-carboxylic
acidmethyl ester (2)whichon treatmentwith excess of hydrazine
hydrate forms biphenyl-4-carboxylic acid hydrazide (3). Then
biphenyl-4-carboxylic acid hydrazide and 2-hydroxybenzalde-
hyde were reﬂuxed to form N0-(2-hydroxybenzylidene)biphe-
nyl-4-carbohydrazide (4) which on reaction with acetic
anhydride results in the formation of 1-(5-(biphenyl-4-yl)-2-(2-
hydroxyphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (5). Finally
an equimolar amount of 1-(5-(biphenyl-4-yl)-2-(2-hydroxy-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone and appropriate
aromatic amines were reﬂuxedwith a catalytic amount of glacial
acetic acid to form substituted oxadiazole derivatives (6a–6r).
The purity of the compounds was checked by thin layer chroma-
tography (TLC) and elemental analyses. The physical constants
of synthesized compounds are given in Table 1.
3.1. Synthesis of biphenyl-4-carboxylic acid methyl ester (2)
A mixture of (50 g, 0.25 mol) biphenyl-4-carboxylic acid and
excess of methanol (250 ml) with 1 mL of sulphuric acid was
reﬂuxed for 5 h in a round bottom ﬂask. The mixture was
cooled; the solid was separated by ﬁltration and recrystallized
from methanol.
3.2. Synthesis of biphenyl-4-carboxylic acid hydrazide (3)
A mixture of (42.4 g, 0.2 mol) biphenyl-4-carboxylic acid
methyl ester and excess of hydrazine hydrate (15 ml,
0.30 mol) and ethanol (250 ml) were reﬂuxed for about 3 h
and cooled. The solid was separated by ﬁltration and recrystal-
lized from ethanol to afford biphenyl-4-carboxylic acid
hydrazide.
3.3. Synthesis of N0-(2-hydroxybenzylidene)biphenyl-4-
carbohydrazide (4)
A mixture of (5.3 g, 0.025 mol) biphenyl-4-carboxylic acid
hydrazide and 2-hydroxybenzaldehyde (3.05 g, 0.025 mol)
Table 1 Physical constants of the synthesized compounds.
N N
O
CH3
N
HO
R
(6a-6r)
.Compound no. R Molecular formula Molecular weight Yield (%) Mp (C)
6a 2F C28H22FN3O 451.49 72 192–194
6b 3F C28H22FN3O 451.49 69 183–185
6c 4F C28H22FN3O 451.49 64 214–216
6d 2Cl C28H22ClN3O2 467.95 65 177–179
6e 3Cl C28H22ClN3O2 467.95 58 182–184
6f 4Cl C28H22ClN3O2 467.95 68 219–221
6 g 2Br C28H22BrN3O2 512.40 75 227–229
6 h 3Br C28H22BrN3O2 512.40 63 211–213
6i 4Br C28H22BrN3O2 512.40 61 217–219
6j 2NO2 C28H22N4O4 478.50 77 225–227
6 k 3NO2 C28H22N4O4 478.50 63 208–210
6 l 4NO2 C28H22N4O4 478.50 73 224–226
6 m 2CH3 C29H25N3O2 447.23 58 197–199
6n 3CH3 C29H25N3O2 447.23 63 209–211
6o 4CH3 C29H25N3O2 447.23 65 206–208
6p 2OCH3 C29H25N3O3 463.53 55 214–216
6q 3OCH3 C29H25N3O3 463.53 63 207–209
6r 4OCH3 C29H25N3O3 463.53 67 231–233
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catalytic amount of glacial acetic acid. The mixture was
cooled; the solid was separated by ﬁltration and recrystallized
from methanol to give the corresponding hydrazide
hydrazone.
3.4. Synthesis of 1-(5-(biphenyl-4-yl)-2-(2-hydroxyphenyl)-
1,3,4-oxadiazol-3(2H)-yl)ethanone (5)
A mixture of N0-(2-hydroxybenzylidene)biphenyl-4-carbohyd-
razide (0.01 mol, 3.16 g) with 5 ml of acetic anhydride was re-
ﬂuxed for 7 h until the completion of the reaction which was
monitored by TLC.
Phenols, unlike amines cannot be acetylated satisfactorily
with acetic anhydride. Usually phenols get acetylated with ace-
tic anhydride/acetyl chloride in the presence of catalyst
(HgCl2, TMS-Cl, Zncl2, ZnO, Mg (Clo4), SmI2). On the other
hand N-acetylation is more feasible as compared to phenol
acetylation. That is why only –NH gets acetylated and the res-
idue was poured onto crushed ice (Mulla et al., 2012). The so-
lid thus obtained was ﬁltered; washed with water and was then
recrystallized with aqueous methanol. Yield 77 %; m.p. 175–
177 C; IR (KBr; cm1): 3452, 2951, 2862, 2840, 1681, 1568,
1179, and 1143. 1H-NMR (300 MHz, DMSO-d6, d ppm):
9.82 (s,1H, OH, D2O exchangeable), 7.91–7.58 (m, 9H, biphe-
nyl H), 6.85–6.62 (m, 4H, phenol), 5.72 (s, 1H, oxadiazole),
2.11 (s, 3H, O‚C–CH3);
13C-NMR (400 MHz, DMSO d6, d
ppm): 167.59, 155.38, 154.17, 142.12, 139.85, 130.55, 129.74,
129.57, 128.03, 127.91, 127.65, 120.82, 114.74, 67.33, and22.72. Anal.: Calcd. for C22H18N2O3. (358.39) C 73.73, H
5.06, N 7.82. Found: C 73.65, H 5.11, and N 7.85.
3.5. General procedure for synthesis of substituted oxadiazole
derivatives (6a–6r)
A mixture of 1-(5-(biphenyl-4-yl)-2-(2-hydroxyphenyl)-1,3,4-
oxadiazol-3(2H)-yl)ethanone (1.79 g, 0.005 mol) and an equi-
molar amount of appropriate aromatic amines (0.01 mol) were
added to 25 ml of absolute ethanol (99.9%) with a drop of gla-
cial acetic acid, and were heated under reﬂux for 9–11 h until
the completion of the reaction that was monitored by TLC.
The obtained precipitate was ﬁltered-off; washed with cold eth-
anol and recrystallized from absolute ethanol.
3.6. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(2-
ﬂuorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6a)
IR (t, cm1): 3452, 2955, 2865, 2838, 1688, 1578, 1277, 1185,
and 1165. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.86 (s,
1H, OH, D2O exchangeable), 7.87-7.55 (m, 9H, Ar H), 7.62-
7.39 (m, 4H, phenyl), 6.89-6.67 (m, 4H, phenol), 5.64 (s, 1H,
oxadiazole), 2.25 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.72, 155.35, 153.18, 143.36, 139.25,
135.27, 130.35, 129.74, 127.15, 126.88, 125.18, 122.78, 120.73,
117.91, 114.25, 68.95, and 20.53. Anal.: Calcd. for
C28H22FN3O2 (451.49): C 74.49, H 4.91, N 9.31. Found: C
74.82, H 4.87, and N 9.22.
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ﬂuorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6b)
IR (t, cm1): 3455, 2988, 2861, 2840, 1685, 1569, 1256, 1183,
and 1155. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.92 (s,
1H, OH, D2O exchangeable), 8.19-7.89 (m, 9H, Ar H), 7.54-
7.38 (m, 4H, phenyl), 6.95-6.68 (m, 4H, phenol), 5.69 (s, 1H,
oxadiazole), 2.37 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.18, 162.83, 155.28, 153.25, 149.29,
142.34, 140.87, 130.74, 129.75, 128.59, 127.84, 120.81, 118.82,
114.77, 114.22, 108.91, 69.32, and 22.72. Anal.: Calcd. for
C28H22FN3O2 (451.49): C 74.49, H 4.91, N 9.31. Found: C
74.43, H 4.94, and N 9.34.
3.8. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(4-
ﬂuorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6c)
IR (t, cm1): 3439, 2979, 2863, 2843, 1688, 1567, 1252, 1175,
and 1162. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.95 (s,
1H, OH, D2O exchangeable), 8.25-7.92 (m, 9H, Ar H), 7.59-
7.34 (m, 4H, phenyl), 6.87-6.55 (m, 4H, phenol), 5.55 (s, 1H,
oxadiazole), 2.35 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.59, 160.35, 155.26, 154.38, 153.39,
146.38, 142.18, 130.83, 129.78, 128.75, 127.15, 122.59, 120.38,
115.85, 114.64, 69.72, and 22.36. Anal.: Calcd. for
C28H22FN3O2 (451.49): C 74.49, H 4.91, N 9.31. Found: C
74.55, H 4.93, and N 9.23.
3.9. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(2-
chlorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6d)
IR (t, cm1): 3438, 2975, 2860, 2840, 1679, 1562, 1188, 1159,
and 739. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.87 (s,
1H, OH, D2O exchangeable), 8.25-7.83 (m, 9H, Ar H), 7.69-
7.32 (m, 4H, phenyl), 6.90-6.71 (m, 4H, phenol), 5.72 (s, 1H,
oxadiazole), 2.35 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.53, 155.39, 153.89, 143.27, 139.75,
138.29, 130.88, 129.63, 129.17, 128.74, 128.11, 127.89, 127.43,
121.37, 119.74, 115.75, 69.74, and 22.87. Anal.: Calcd. for
C28H22ClN3O2 (467.95): C 71.87, H 4.74, N 8.98. Found: C
71.94, H 4.79, and N 8.86.
3.10. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(3-
chlorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6e)
IR (t, cm1): 3435, 2972, 2861, 2843, 1675, 1566, 1184, 1133,
and 725. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.88 (s,
1H, OH, D2O exchangeable), 8.39-7.85 (m, 9H, Ar H), 7.65-
7.29 (m, 4H, phenyl), 6.86-6.68 (m, 4H, phenol), 5.71 (s, 1H,
oxadiazole), 2.32 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.85, 154.39, 153.93, 149.95, 143.29,
139.75, 133.81, 130.75, 129.75, 128.19, 128.05, 127.91, 127.45,
121.63, 119.78, 114.87, 69.71, and 22.78. Anal.: Calcd. for
C28H22ClN3O2 (467.95): C 71.87, H 4.74, N 8.98. Found: C
71.83, H 4.77, and N 8.99.3.11. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(4-
chlorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6f)
IR (t, cm1): 3439, 2965, 2865, 2837, 1683, 1565, 1182, 1121,
and 735. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.81 (s,
1H, OH, D2O exchangeable), 8.49-8.03 (m, 9H, Ar H), 7.61-
7.39 (m, 4H, phenyl), 6.91-6.68 (m, 4H, phenol), 5.76 (s, 1H,
oxadiazole), 2.39 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.28, 155.38, 154.19, 149.85, 142.18,
139.77, 133.87, 130.85, 129.47, 128.46, 127.41, 126.48, 126.15,
121.29, 119.87, 114.75, 69.75, and 22.81. Anal.: Calcd. for
C28H22ClN3O2 (467.95): C 71.87, H 4.74, N 8.98. Found: C
71.83, H 4.78, and N 8.98.
3.12. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(2-
bromophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6g)
IR (t, cm1): 3432, 2962, 2855, 2842, 1688, 1566, 1185, 1127,
and 639. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.85 (s,
1H, OH, D2O exchangeable), 8.59-8.17 (m, 9H, Ar H), 7.66-
7.31 (m, 4H, phenyl), 6.87-6.54 (m, 4H, phenol), 5.68 (s, 1H,
oxadiazole), 2.35 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.37, 155.39, 154.86, 145.29, 142.77,
139.48, 131.84, 130.73, 129.71, 128.85, 128.37, 127.32, 126.54,
120.81, 118.52, 117.59, 114.35, 69.22, and 22.89. Anal.: Calcd.
for C28H22BrN3O2 (512.40): C 65.63, H 4.33, N 8.20. Found: C
65.81, H 4.21, and N 8.14.
3.13. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(3-
bromophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6h)
IR (t, cm1): 3439, 2968, 2859, 2839, 1685, 1569, 1184, 1118,
and 645. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.87 (s,
1H, OH, D2O exchangeable), 8.67-8.24 (m, 9H, Ar H), 7.61-
7.34 (m, 4H, phenyl), 6.89-6.73 (m, 4H, phenol), 5.87 (s, 1H,
oxadiazole), 2.42 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.81, 155.29, 154.42, 150.48, 142.85,
139.87, 131.87, 130.15, 129.38, 128.54, 127.53, 124.18, 123.19,
122.71, 121.87, 114.82, 69.55, and 22.85. Anal.: Calcd. for
C28H22BrN3O2 (512.40): C 65.63, H 4.33, N 8.20. Found: C
65.57, H 4.32, and N 8.27.
3.14. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(4-
bromophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6i)
IR (t, cm1): 3436, 2958, 2863, 2845, 1682, 1563, 1182, 1119,
and 637. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.85 (s,
1H, OH, D2O exchangeable), 8.62-8.23 (m, 9H, Ar H), 7.77-
7.31 (m, 4H, phenyl), 6.84-6.75 (m, 4H, phenol), 5.83 (s, 1H,
oxadiazole), 2.49 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz,
DMSO-d6, d ppm): 163.56, 155.39, 154.17, 150.35, 142.11,
140.39, 132.31, 130.87, 129.79, 129.62, 128.75, 127.94, 127.55,
121.38, 120.93, 114.73, 69.81, and 22.64. Anal.: Calcd. for
C28H22BrN3O2 (512.40): C 65.63, H 4.33, N 8.20. Found: C
65.60, H 4.27, and N 8.29.
S1026 M. Malhotra et al.3.15. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(2-
nitrophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6j)
IR (t, cm1): 3431, 2975, 2855, 2843, 1680, 1572, 1552, 1358,
1181, and 1129. 1H-NMR (300 MHz, DMSO-d6, d ppm):
9.83 (s, 1H, OH, D2O exchangeable), 8.55-8.15 (m, 9H, Ar
H), 7.78-7.56 (m, 4H, phenyl), 6.87-6.76 (m, 4H, phenol),
5.44 (s, 1H, oxadiazole), 2.35 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.59, 155.83, 154.11,
144.55, 142.91, 141.88, 140.15, 131.38, 129.24, 128.45, 128.09,
127.94, 127.65, 124.75, 120.58, 114.91, 69.58, and 22.75. Anal.:
Calcd. for C28H22N4O4 (478.50): C 70.28, H 4.63, N 11.71.
Found: C 70.35, H 4.60, and N 11.67.
3.16. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(3-
nitrophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6k)
IR (t, cm1): 3455, 2990, 2858, 2846, 1686, 1575, 1557, 1335,
1192, and 1135. 1H-NMR (300 MHz, DMSO-d6, d ppm):
9.89 (s, 1H, OH, D2O exchangeable), 8.59-8.21 (m, 9H, Ar
H), 7.81-7.59 (m, 4H, phenyl), 6.85-6.69 (m, 4H, phenol),
5.54 (s, 1H, oxadiazole), 2.39 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.94, 155.84, 154.37,
148.75, 148.13, 142.11, 140.19, 131.94, 130.88, 129.84, 128.53,
127.84, 127.43, 121.48, 120.59, 117.75, 114.73, 69.53, and
22.81. Anal.: Calcd. for C28H22N4O4 (478.50): C 70.28, H
4.63, N 11.71. Found: C 70.35, H 4.66, and N 11.61.3.17. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(4-
nitrophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6l)
IR (t, cm1): 3443, 2972, 2856, 2841, 1683, 1575, 1555, 1351,
1177, and 1139. 1H-NMR (300 MHz, DMSO-d6, d ppm):
9.79 (s, 1H, OH, D2O exchangeable), 8.51-8.22 (m, 9H, Ar
H), 7.75-7.38 (m, 4H, phenyl), 6.89-6.73 (m, 4H, phenol),
5.59 (s, 1H, oxadiazole), 2.38 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.84, 157.64, 155.65,
154.32, 145.91, 142.18, 139.72, 130.29, 129.83, 129.65, 128.54,
127.85, 127.64, 125.57, 123.25, 120.55, 114.73, 69.57, and
22.45. Anal.: Calcd. for C28H22N4O4 (478.50): C 70.28, H
4.63, N 11.71. Found: C 70.22, H 4.65, and N 11.75.3.18. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(o-tolylimino)ethyl)-2,3-
dihydro-1,3,4-oxadiazol-2-yl)phenol (6m)
IR (t, cm1): 3425, 2969, 2858, 2845, 1681, 1564, 1183, and
1128. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.72 (s, 1H,
OH, D2O exchangeable), 8.48-8.15 (m, 9H, Ar H), 7.77-7.33
(m, 4H, phenyl), 6.87-6.64 (m, 4H, phenol), 5.60 (s, 1H, oxadi-
azole), 2.42 (s, 3H, CH3), 2.15 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.52, 155.46, 153.97, 142.35,
139.87, 135.27, 130.77, 129.58, 129.11, 128.51, 127.79, 127.17,
126.25, 120.59, 114.29, 70.12, 22.27, and 19.35. Anal.: Calcd.
for C29H25N3O2 (447.23): C 77.83, H 5.63, N 9.39. Found: C
77.88, H 5.65, and N 9.32.3.19. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(m-tolylimino)ethyl)-2,3-
dihydro-1,3,4-oxadiazol-2-yl)phenol (6n)
IR (t, cm1): 3431, 2965, 2855, 2841, 1685, 1562, 1184, and
1125. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.77 (s, 1H,
OH, D2O exchangeable), 8.52-8.19 (m, 9H, Ar H), 7.76-7.31
(m, 4H, phenyl), 6.77-6.69 (m, 4H, phenol), 5.62 (s, 1H, oxadi-
azole), 2.39 (s, 3H, CH3), 2.09 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.59, 155.39, 154.21, 151.18,
142.27, 139.71, 139.15, 130.19, 129.94, 129.73, 129.35, 128.18,
127.59, 123.88, 120.93, 118.85, 114.71, 69.71, and 22.78. Anal.:
Calcd. for C29H25N3O2 (447.23): C 77.83, H 5.63, N 9.39.
Found: C 77.81, H 5.55, and N 9.49.
3.20. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(p-tolylimino)ethyl)-2,3-
dihydro-1,3,4-oxadiazol-2-yl)phenol (6o)
IR (t, cm1): 3432, 2965, 2861, 2841, 1683, 1563, 1185, and
1132. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.74 (s, 1H,
OH, D2O exchangeable), 8.41-8.11 (m, 9H, Ar H), 7.69-7.44
(m, 4H, phenyl), 6.65-6.37 (m, 4H, phenol), 5.62 (s, 1H, oxadi-
azole), 2.53 (s, 3H, CH3), 2.19 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.83, 155.39, 154.15, 148.29,
142.17, 139.77, 137.15, 130.72, 130.12, 129.72, 129.13, 128.15,
127.87, 127.57, 125.74, 120.19, 114.72, 69.74, and 22.55. Anal.:
Calcd. for C29H25N3O2 (447.23): C 77.83, H 5.63, N 9.39.
Found: C 77.89, H 5.61, and N 9.35.3.21. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(2-
methoxyphenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6p)
IR (t, cm1): 3459, 2976, 2852, 2846, 1687, 1571, 1176, and
1165. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.86 (s, 1H,
OH, D2O exchangeable), 8.58-8.19 (m, 9H, Ar H), 7.79-7.31
(m, 4H, phenyl), 6.68-6.51 (m, 4H, phenol), 5.47 (s, 1H, oxadi-
azole), 3.84 (s, 3H, OCH3, 2.27 (s, 3H, N‚C–CH3);
13C-NMR
(400 MHz, DMSO-d6, d ppm): 163.83, 155.77, 154.73, 151.18,
142.53, 139.77, 134.48, 130.75, 129.81, 129.44, 128.37, 127.93,
127.35, 124.33, 122.43, 120.62, 116.84, 69.71, 56.82, and
22.78. Anal.: Calcd. for C29H25N3O3 (463.53): C 75.14, H
5.44, N 9.07. Found: C 75.23, H 5.37, and N 9.05.3.22. (Z)-2-(5-(biphenyl-4-yl)-3-(1-(3-
methoxyphenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6q)
IR (t, cm1): 3443, 2976, 2860, 2842, 1684, 1566, 1171, and
1143. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.75 (s, 1H,
OH, D2O exchangeable), 8.54-8.19 (m, 9H, Ar H), 7.71-
7.28 (m, 4H, phenyl), 6.83-6.66 (m, 4H, phenol), 5.51 (s,
1H, oxadiazole), 3.81 (s, 3H, OCH3), 2.34 (s, 3H, N‚C–
CH3);
13C-NMR (400 MHz, DMSO-d6, d ppm): 163.82,
160.91, 155.38, 153.29, 149.74, 142.73, 139.64, 131.69,
129.38, 128.11, 127.92, 127.54, 127.05, 120.79, 114.75,
113.67, 107.55, 105.19, 69.54, 54.11, and 22.72. Anal.: Calcd.
for C29H25N3O3 (463.53): C 75.14, H 5.44, N 9.07. Found:
C 75.25, H 5.39, and N 9.01.
Table 2 Antibacterial zone of inhibition (mm) of synthesized
oxadiazoles.
Compoundb Conc. (lg/ml)Zone of inhibition (mm)
B. subtilisS. aureusP. aeruginosaE. coli
6a 100 11 12 14 15
200 13 14 16 17
6b 100 10 11 15 16
200 12 13 18 18
6c 100 12 15 23 18
200 14 17 24 21
6d 100 14 12 18 19
200 16 15 20 21
6e 100 15 14 21 18
200 17 16 23 20
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methoxyphenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-
yl)phenol (6r)
IR (t, cm1): 3437, 2971, 2863, 2843, 1685, 1561, 1175, and
1143. 1H-NMR (300 MHz, DMSO-d6, d ppm): 9.71 (s, 1H,
OH, D2O exchangeable), 8.51-8.20 (m, 9H,biphenyl H), 7.82-
7.33 (m, 4H, phenyl), 6.87-6.59 (m, 4H, phenol), 5.45 (s, 1H,
oxadiazole), 3.89 (s, 3H, OCH3), 2.39 (s, 3H, N‚C–CH3);
13C-NMR (400 MHz, DMSO-d6, d ppm): 163.48, 158.41,
154.51, 153.35, 143.92, 142.18, 139.74, 130.83, 129.61, 128.26,
127.73, 127.41, 127.03, 121.20, 119.77, 114.62, 69.75, 54.11,
22.68. Anal.: Calcd. for C29H25N3O3 (463.53): C 75.14, H
5.44, N 9.07. Found: C 75.07, H 5.48, N 9.10.6f 100 17 18 24 22
200 19 20 27 25
6 g 100 11 13 15 17
200 13 15 18 19
6 h 100 11 14 19 18
200 12 16 22 20
6i 100 13 17 25 21
200 15 18 27 23
6j 100 16 14 22 19
200 18 17 24 22
6 k 100 15 16 25 22
200 17 18 28 24
6 l 100 18 21 30 25
200 20 23 32 26
6 m 100 9 8 15 12
200 11 10 18 14
6n 100 10 10 19 15
200 12 13 22 17
6o 100 12 15 23 19
200 14 16 25 21
6p 100 10 11 19 15
200 12 13 22 16
6q 100 11 15 22 17
200 13 17 24 19
6r 100 12 16 25 21
200 14 18 26 23
Ciproﬂoxacina100 21 23 32 26
200 22 24 33 27
a Ciproﬂoxacin (100, 200 lg per disc) was used as positive refer-
ence standard antibiotic discs and Synthesized compounds (100,
200 lg per disc).
b Synthesized compounds 6a–6r.4. Antimicrobial Evaluation
The newly synthesized compounds were screened for their anti-
bacterial activity against Bacillus subtilis (MTCC 96), Staphy-
lococcus aureus (MTCC 121), Pseudomonas aeruginosa (MTCC
2453) and Escherichia coli (MTCC 40) bacterial strains by the
disc-diffusion method (Cruickshank et al., 1975; Collins,
1976). A standard inoculum (1–2 · 107 c.f.u./ml 0.5 McFar-
land standards) was introduced on the surface of sterile agar
plates, and a sterile glass spreader was used for even distribu-
tion of the inoculum. A disc measuring 6.25 mm in diameter
was prepared from Whatman No. 1 ﬁlter paper and sterilized
by dry heat at 140 C for 1 h. The sterile disc previously soaked
with the test compound solution in DMSO of speciﬁc concen-
trations 100 lg and 200 lg/disc was carefully placed on the
agar culture plates. The plates were inverted and incubated
for 24 h at 37 C. Ciproﬂoxacin was used as a standard drug.
Inhibition zones were measured and compared with the con-
trols. The bacterial zones of inhibition were given in Table 2.
Minimum inhibitory concentrations (MICs) were determined
by the broth dilution technique. The nutrient broth, which
contained logarithmic serially two fold diluted amount of the
test compound and control was inoculated with approximately
5 · 105 c.f.u (colony forming unit) of actively dividing bacteria
cells. The cultures were incubated for 24 h at 37 C and the
growth was monitored visually and spectrophotometrically.
The lowest concentration (highest dilution) required to arrest
the growth of bacteria was regarded as minimum inhibitory
concentration (MIC).
To obtain the minimum bactericidal concentration (MBC),
0.1 ml volume was taken from each tube and spread on agar
plates. The number of c.f.u was counted after 18–24 h of incu-
bation at 35 C. MBC was deﬁned as the lowest drug concen-
tration at which 99.9% of the inoculum was killed. The
minimum inhibitory concentration and minimum bactericidal
concentrations are given in Table 3.
The newly synthesized compounds were screened for their
antifungal activity against Candida albicans (MTCC 8184)
and Aspergillus niger (MTCC 8189) in DMSO by the agar dif-
fusion method (Khan, 1997; Varma, 1998) Sabouraud’s agar
medium was prepared by dissolving peptone (1 g), D-glucose
(4 g) and agar (2 g) in distilled water (100 ml) and adjusting
pH to 5.7. Normal saline was used to make a suspension of
spore of fungal strain for lawing. A loopful of particular fungal
strain was transferred to 3 ml saline to get a suspension of the
corresponding species. Twenty millilitres of agar media waspoured into each Petri dish. Excess of suspension was decanted
and the plates were dried by placing in an incubator at 37 C
for 1 h. Using an agar punch, wells were made and each well
was labelled. A control was also prepared in triplicate and
maintained at 37 C for 3–4 days. The fungal activity of each
compound was compared with voriconazole as a standard
drug. Inhibition zones were measured and compared with
the controls. The fungal zones of inhibition values are given
in Table 4.
The nutrient broth, which contained logarithmic serially
two fold diluted amount of test compound and controls was
inoculated with approximately 1.6 · 104–6 · 104 c.f.u./ml.
The cultures were incubated for 48 h at 35 C and the growth
was monitored. The lowest concentration (highest dilution) re-
quired to arrest the growth of fungus was regarded as mini-
Table 3 MIC and MBC results of oxadiazoles.
Compounds B. subtilis S. aureus P. aeruginosa E. coli
MICa MBCb MICa MBCb MICa MBCb MICa MBCb
6a 25 50 12.5 50 25 50 12.5 25
6b 50 100 25 50 12.5 25 25 50
6c 12.5 25 12.5 25 50 100 25 50
6d 6 12.5 25 50 12.5 25 12.5 25
6e 12.5 25 25 50 12.5 25 6 12.5
6f 6 12.5 6 12.5 6 12.5 12.5 25
6 g 12.5 50 12.5 25 6 12.5 6 12.5
6 h 25 50 12.5 25 6 12.5 6 12.5
6i 12.5 25 12.5 25 6 12.5 6 12.5
6j 12.5 50 12.5 25 6 12.5 25 50
6 k 12.5 25 12.5 25 6 12.5 6 12.5
6 l 6 12.5 6 12.5 12.5 25 6 12.5
6 m 25 50 25 50 25 50 50 100
6n 12.5 25 25 50 25 50 12.5 25
6o 12.5 25 12.5 25 25 50 12.5 25
6p 25 50 12.5 25 6 12.5 12.5 25
6q 12.5 25 12.5 25 6 12.5 12.5 25
6r 12.5 25 6 12.5 6 12.5 12.5 25
Stdc 6 12.5 6 12.5 6 12.5 6 12.5
a MIC (lg/ml) = minimum inhibitory concentration, i.e., the lowest concentration to completely inhibit bacterial growth.
b MBC (lg/ml) = minimum bactericidal concentration, i.e., the lowest concentration to completely kill bacteria.
c Ciproﬂoxacin is used as standard drug.
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fungicidal concentration (MFC), 0.1 ml volume was taken
from each tube and spread on agar plates. The number of
c.f.u was counted after 48 h of incubation at 35 C. MFC
was deﬁned as the lowest drug concentration at which 99.9%
of the inoculum was killed. The minimum inhibitory, mini-
mum bactericidal and minimum fungicidal concentrations
are given in Table 5.
5. Antioxidant activity
Antioxidant activity is determined in terms of hydrogen perox-
ide scavenging activity. The solution of hydrogen peroxide
(40 mM) was prepared in phosphate buffer (pH 7.4). Different
concentrations (100, 300, and 500 lg/mL) of all the synthe-
sized compounds were added to a hydrogen peroxide solution
(0.6 mL, 40 mM). The absorbance of hydrogen peroxide at
230 nm was determined after 10 min against a blank solution
containing phosphate buffer without hydrogen peroxide. The
percentage scavenging of hydrogen peroxide of the synthesized
compounds and the standard compounds was calculated using
the following formula: Percentage scavenging
[H2O2] = [(A0  A1)/A0] · 100, where A0 was the absorbance
of the blank, and A1 was the absorbance in the presence of
the sample and standards (Gulcin et al., 2005). The percentage
scavenging of hydrogen peroxide by the synthesized com-
pounds at 100, 300 and 500 lg/mL concentrations was calcu-
lated and results are summarized in Table 6.6. Result and discussion
Nevertheless, the structures of all new compounds synthesized
were conﬁrmed by (IR, 1H NMR and 13C NMR) spectra. The
IR spectra of all compound (6a–6r) showed absorption band ataround 3459-3425, 2995-2958, 2865-2835, 1688-1675, 1578-
1561, 1188-1171, and 1173-1118 cm1 regions, conforming
the presence of OH, CH, CH2, C‚N, C‚C, C–O, and C–N
respectively. In the 1H NMR spectra, the signals of the respec-
tive prepared derivatives were veriﬁed on the basis of their
chemical shifts, multiplicities, and coupling constants. The
spectra of most compounds showed the characteristic 1H pro-
ton of OH at around d 9.95-9.71, 9H proton of biphenyl at
around d 8.69-7.55, characteristic protons of phenyl at d
7.82-7.28 ppm, 3H proton of phenol appearing at 6.95-6.37,
1H proton of oxadiazole at 5.87-5.43, and 3H proton of
N‚C–CH3 around d 2.49-2.09 ppm.
13C-NMR spectra of
compounds showed characteristic signals appearing for
N‚C–CH3 at d 163.94-163.18, oxadiazole ring at d 155.84-
68.95, phenyl ring at d 162.83-108.91, biphenyl moiety at d
131.94-127.03, phenol at d 160.35-114.22 and N‚C–CH3 at
d 22.89-19.35 ppm.
The investigation of antibacterial screening data revealed
that all the tested compounds showed moderate to good anti-
bacterial and antifungal activities against B. subtilis, S. aureus,
P. aeruginosa, E. coli, C. albicans and A. niger respectively. The
compounds 6f, 6l and 6r displayed excellent antibacterial activ-
ity while 6e, 6j and 6k showed moderate antibacterial activity
and the compounds 6b, 6m and 6p are less active as compared
to standard drug ciproﬂoxacin. In case of antifungal activity
compounds 6c, 6l and 6q exhibit signiﬁcant activity while the
compounds 6h, 6j, 6m, 6o and 6k showed moderate activity.
Among all the synthesized derivatives the compound 6n was
found to be the least active compound against fungal strain.
All the synthesized compounds exhibited potent hydrogen per-
oxide scavenging activities. From all the synthesized com-
pound analogues 6l with nitro moiety was the most active
with scavenging of hydrogen peroxide of 58.18 at 500 lg/mL
concentration, followed by compound 6q with methoxy group
with hydrogen peroxide scavenging of 57.36 at 500 lg/mL.
Table 6 Hydrogen peroxide scavenging activity of synthesized
compounds.
Comp. Scavenging of hydrogen peroxide at
diﬀerent concentrations (%)
100 lg 300 lg 500 lg
6a 41.55 39.84 41.22
6b 46.34 44.55 45.77
6c 51.11 48.12 44.59
6d 41.92 42.33 41.72
6e 45.65 46.19 45.91
6f 51.21 43.12 39.57
6 g 39.58 42.61 43.18
6 h 43.45 41.37 45.27
6i 41.88 45.19 48.11
6j 47.52 54.15 53.18
6 k 45.35 50.27 52.15
6 l 51.15 52.27 58.18
6 m 45.87 41.37 41.93
6n 42.98 39.72 39.57
6o 41.03 43.06 44.14
6p 51.62 52.18 52.91
6q 54.18 53.76 57.36
6r 49.87 51.35 48.74
BHA 63.27 66.19 68.25
Ascorbic Acid 51.47 53.45 55.38
Table 4 Antifungal zone of inhibition (mm) of oxadiazoles.
Compoundsb Conc. (lg/ml) Zone of inhibition (mm)
C. albicans A. niger
6a 100 15 18
200 17 20
6b 100 16 17
200 18 19
6c 100 21 25
200 23 26
6d 100 12 13
200 15 15
6e 100 13 15
200 14 17
6f 100 15 20
200 15 20
6 g 100 12 18
200 15 20
6 h 100 19 23
200 21 25
6i 100 16 22
200 18 24
6j 100 16 15
200 19 18
6 k 100 18 23
200 20 25
6 l 100 21 27
200 24 29
6 m 100 17 19
200 20 22
6n 100 11 16
200 14 18
6o 100 16 20
200 19 23
6p 100 16 20
200 18 21
6q 100 20 23
200 23 26
6r 100 18 20
200 19 22
Voriconazolea 100 25 24
200 27 26
a Voriconazole (100, 200 lg per disc) was used as positive refer-
ence standard antibiotic discs, and Synthesized compounds (100,
200 lg per disc).
b Synthesized compounds 6a–6r.
Table 5 MIC and MFC results of oxadiazoles.
Compounds C. albicans A. niger
MICa MFCb MICa MFCb
6a 25 100 6 12.5
6b 12.5 25 25 100
6c 6 12.5 6 12.5
6d 25 50 - -
6e - - 6 25
6f 12.5 25 25 50
6 g 25 50 12.5 25
6 h 6 12.5 12.5 25
6i 12.5 25 6 12.5
6j 6 12.5 12.5 25
6 k 6 12.5 12.5 25
6 l 6 12.5 6 12.5
6 m 12.5 25 12.5 25
6n 12.5 25 6 12.5
6o 25 50 25 50
6p 6 25 25 50
6q 6 12.5 6 12.5
6r 6 12.5 25 50
Stdc 6 12.5 25 50
a MIC (lg/ml) = minimum inhibitory concentration, i.e., the
lowest concentration to completely inhibit fungal growth;
b MFC (lg/ml) = minimum fungicidal concentration, i.e., the
lowest concentration to completely kill the fungi.
c Voriconazole is used as standard drug.
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and investigate the antimicrobial and antioxidant activity of
newly synthesized oxadiazole containing compounds that are
structurally related to the famous antimicrobial oxadiazole
pharmacophore, with the hope of discovering new structure
leads serving as potential broad spectrum antimicrobial and
antioxidant activities. The obtained results revealed that 18
compounds were able to display growth inhibitory effects on
the tested Gram-positive B. subtilis, S. aureus and Gram-neg-
ative bacteria P. aeruginosa, E. coli. Meanwhile, three com-
pounds 6f, 6l and 6r displayed excellent activity against
Gram-positive bacteria and Gram-negative bacteria mean-
while, three compounds 6c, 6l and 6q exhibit promising anti-
fungal activity against C. albicans and A. niger. Structurally,
the antimicrobial and antioxidant potential of the active com-pound depends on the nature of the substituents: remarkabe
antibacterial and antifungal activities were encountered with
the p-nitro phenyl moiety of the oxadiazole counterpart 6l,
while the obtained antifungal activity conformed to those com-
prising compounds having p-ﬂuoro, p-nitro and m-methoxy
COOH COOCH3
i
(1) (2)
ii
CONHN=C CONHNH2
HO
H
iii
(4) (3)
iv
N
N
O
CH3
O
HO
N N
O
CH3
N
HO
R
v
(5) (6a-6r)                                                                              
Scheme 1 Reagents and conditions: (i) Methanol, reﬂux, 5 h, 84.43%; (ii) NH2NH2.H2O, reﬂux, 3 h, 86.79%; (iii) 2-OHC6H4, ethanol,
CH3COOH, reﬂux, 5 h, 81% (iv) (CH3CO)2O, reﬂux, 7 h, 77% (v) Ethanol, CH3COOH, aromatic amines, reﬂux, 9–11 h, 55–77%.
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compound 6l proved to be the most active antimicrobial mem-
ber within this study with a considerable broad spectrum activ-
ity against all bacterial and fungal strains. From the results it is
concluded that the introduction of p-nitro phenyl moiety
along with oxadiazole pharmacophore 6l resulted in potent
hydrogen peroxide scavenging activity. It may be due to nitro
substitution at the para position of phenyl nucleus along with
oxadiazole moiety which supports its therapeutic activity. So,
from the results it has revealed that the nature and position of
the substituent has shown a marked effect on antimicrobial
and antioxidant activities. (See Scheme 1).
7. Conclusion
This study reports the synthesis of (Z)-2-(5-(biphenyl-4-yl)-3-
(1-(imino)ethyl)-2,3-dihydro-1,3,4 oxadiazol-2-yl)phenol
derivatives as potent antimicrobial and antioxidant agents
(6a–6r) and were characterized by spectral analysis. The ob-
tained results revealed that most of the synthesized analogues
have shown prominent antimicrobial and antioxidant activi-
ties. It was observed that the analogues (6f) (Z)-2-(5-(biphe-
nyl-4-yl)-3-(1-(4-chlorophenylimino)ethyl)-2,3-dihydro-1,3,4-
oxadiazol-2-yl)phenol and (6l) (Z)-2-(5-(biphenyl-4-yl)-3-(1-(4-
nitrophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)phe-
nol have shown excellent antibacterial activity rather in case ofantifungal activity the analogues (6c) (Z)-2-(5-(biphenyl-4-yl)-
3-(1-(4-ﬂuorophenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-
2-yl)phenol, (6l) and (6q) (Z)-2-(5-(biphenyl-4-yl)-3-(1-(3-
methoxyphenylimino)ethyl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)
phenol exhibit prominent activity. Among all the synthesized
compounds the analogue 6l exhibits potent antioxidant activ-
ity. So, these new therapeutic agents could be considered as
lead molecule for the future development of drugs which
could be used as antimicrobial and antioxidant agents.
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